Chandler H. Park

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor, Johann S. de Bono, Kim N. et al. · New England Journal of Medicine · 2021 · 2.3K citations · Full text

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

Michael J. Morris, Johann S. de Bono, Kim N. et al. · Journal of Clinical Oncology · 2021 · 72 citations

Urology, Radiation Medicine, Psma-positive Mcrpc +14

Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3

Petros Grivas, Damien Pouessel, Chandler H. Park et al. · Journal of Clinical Oncology · 2024 · 64 citations · Full text

TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.

Petros Grivas, Damien Pouessel, Chandler H. Park et al. · Journal of Clinical Oncology · 2022 · 35 citations

Cancer Management, Immunology, Immunotherapeutics +20

Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy.

Daniel P. Petrylak, Scott T. Tagawa, Rohit Jain et al. · Journal of Clinical Oncology · 2023 · 22 citations

Preclinical Therapeutics, Immunology, Prior Therapies +25